Literature DB >> 16219454

Systemic effects of COPD.

Marc Decramer1, Fernando De Benedetto, Adriana Del Ponte, Stefano Marinari.   

Abstract

Chronic obstructive pulmonary disease (COPD) is characterised by a range of pathological changes of the respiratory system, including airflow limitation secondary to structural changes of the small airways and loss of alveolar attachments, inflammation, ciliary dysfunction, and increased mucous production. COPD also has significant systemic consequences. The relationships between these pulmonary and nonpulmonary morbidities are not fully understood, and this further complicates the assessment of disease severity and prognosis. Although improving lung function and disease symptoms have been the main focus of COPD management, these parameters alone do not reflect the full burden of disease. More recent endeavours have highlighted the potential role of addressing physical limitations imposed by systemic alterations. It is evident that systemic manifestations are common in COPD. Indeed, many patients demonstrate a gradual and significant weight loss that exacerbates the course and prognosis of disease. This weight loss is often accompanied by peripheral muscle dysfunction and weakness, which markedly contribute to exercise limitation and impaired quality of life. Weight loss has been postulated to be the result of a high metabolic rate that is not compensated for by increased dietary intake. The cause of this elevated metabolism is a matter of much debate, and several factors have been implicated. Similarly, the processes underlying depletion of muscle mass and function have not been fully delineated. The impact of the systemic manifestations of COPD is substantial, and although many attempts have been made to elucidate the mechanisms underlying these manifestations, there are important questions, which remain to be answered. An increase in our understanding in this field will doubtless highlight potential therapeutic targets, and assist in guiding future therapeutic development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16219454     DOI: 10.1016/j.rmed.2005.09.010

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  28 in total

1.  A Comparison between Two Pathophysiologically Different yet Microbiologically Similar Lung Diseases: Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.

Authors:  Daniel E Fenker; Cameron T McDaniel; Warunya Panmanee; Ralph J Panos; Eric J Sorscher; Carleen Sabusap; John P Clancy; Daniel J Hassett
Journal:  Int J Respir Pulm Med       Date:  2018-11-29

2.  Body mass index, respiratory conditions, asthma, and chronic obstructive pulmonary disease.

Authors:  Yong Liu; Roy A Pleasants; Janet B Croft; Njira Lugogo; Jill Ohar; Khosrow Heidari; Charlie Strange; Anne G Wheaton; David M Mannino; Monica Kraft
Journal:  Respir Med       Date:  2015-05-16       Impact factor: 3.415

3.  Chronic cigarette smoking causes hypertension, increased oxidative stress, impaired NO bioavailability, endothelial dysfunction, and cardiac remodeling in mice.

Authors:  M A Hassan Talukder; Wesley M Johnson; Saradhadevi Varadharaj; Jiarui Lian; Patrick N Kearns; Mohamed A El-Mahdy; Xiaoping Liu; Jay L Zweier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-05       Impact factor: 4.733

4.  Ventilatory pattern and energy expenditure are altered in cystic fibrosis mice.

Authors:  Rebecca J Darrah; Ilya R Bederman; Anna L Mitchell; Craig A Hodges; Cara K Campanaro; Mitchell L Drumm; Frank J Jacono
Journal:  J Cyst Fibros       Date:  2013-01-03       Impact factor: 5.482

5.  Elevated levels of IL-18 in plasma and skeletal muscle in chronic obstructive pulmonary disease.

Authors:  A M W Petersen; M Penkowa; M Iversen; L Frydelund-Larsen; J L Andersen; J Mortensen; P Lange; B K Pedersen
Journal:  Lung       Date:  2007-04-10       Impact factor: 2.584

6.  Alterations in the muscle-to-capillary interface in patients with different degrees of chronic obstructive pulmonary disease.

Authors:  Gabriella Eliason; Samy M Abdel-Halim; Karin Piehl-Aulin; Fawzi Kadi
Journal:  Respir Res       Date:  2010-07-15

7.  Development of a modified BODE index as a mortality risk measure among older adults with and without chronic obstructive pulmonary disease.

Authors:  Melissa H Roberts; Douglas W Mapel; Shannon Bruse; Hans Petersen; Toru Nyunoya
Journal:  Am J Epidemiol       Date:  2013-08-08       Impact factor: 4.897

8.  A new experimental model of cigarette smoke-induced emphysema in Wistar rats.

Authors:  Rodrigo de las Heras Kozma; Edson Marcelino Alves; Valter Abraão Barbosa-de-Oliveira; Fernanda Degobbi Tenorio Quirino dos Santos Lopes; Renan Cenize Guardia; Henrique Vivi Buzo; Carolina Arruda de Faria; Camila Yamashita; Manzelio Cavazzana Júnior; Fernando Frei; Maria José de Oliveira Ribeiro-Paes; João Tadeu Ribeiro-Paes
Journal:  J Bras Pneumol       Date:  2014 Jan-Feb       Impact factor: 2.624

9.  Relationship between BODE index, quality of life and inflammatory cytokines in COPD patients.

Authors:  Nurhan Sarioglu; Aylin Ozgen Alpaydin; Aysın Sakar Coskun; Pınar Celik; Beyhan Cengiz Ozyurt; Arzu Yorgancioglu
Journal:  Multidiscip Respir Med       Date:  2010-04-30

10.  Multidimensional analyses to assess the relations between treatment choices by physicians and patients' characteristics: the example of COPD.

Authors:  Nicolas Roche; Christos Chouaid; Bertrand Delclaux; Yan Martinat; Jean-Michel Marcos; Hervé Pégliasco; Bruno Scherrer
Journal:  BMC Pulm Med       Date:  2012-08-06       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.